Roche Holding Net Income From Continuing Ops Over Time
| RO Stock | CHF 364.80 1.40 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Roche Holding Performance and Roche Holding Correlation. Roche |
Cross Equities Net Income From Continuing Ops Analysis
Compare Roche Holding AG and related stocks such as Novartis AG, COSMO Pharmaceuticals, and Siegfried Holding Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NOVN | 7 B | 7 B | 7 B | 7 B | 7 B | 7 B | 6.7 B | 7.7 B | 12.6 B | 7.1 B | 8.1 B | 24 B | 7 B | 8.6 B | 11.9 B | 14 B | 11.5 B |
| COPN | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 248.2 M | 19.3 M | (32.4 M) | (18.1 M) | (24.5 M) | (7.9 M) | 21.7 M | 17.5 M | (4.7 M) | 133.2 M | 119.9 M | 125.9 M |
| SFZN | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 39.1 M | 27.9 M | 39.7 M | 56.3 M | 53.1 M | 60.9 M | 95.6 M | 156.5 M | 112.7 M | 159.9 M | 183.9 M | 193.1 M |
| SOON | 345.8 M | 345.8 M | 345.8 M | 345.8 M | 345.8 M | 345.8 M | 356.2 M | 407.4 M | 460.2 M | 489.5 M | 585.3 M | 663.6 M | 658.3 M | 609.5 M | 547 M | 629 M | 563.5 M |
| GALE | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 81.1 M | 83.4 M | 118.9 M | 147.7 M | 125.3 M | 172.7 M | 168.2 M | 165.9 M | 165.7 M | 183.7 M | 211.3 M | 149.4 M |
| ALC | 308 M | 308 M | 308 M | 308 M | 308 M | 308 M | (170 M) | 256 M | (315 M) | (656 M) | (531 M) | 376 M | 335 M | 974 M | 1 B | 1.2 B | 1.2 B |
| TECN | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 57.1 M | 54.5 M | 66.5 M | 70.7 M | 73.2 M | 103.7 M | 121.7 M | 121.1 M | 132.1 M | 67.7 M | 77.8 M | 90.9 M |
| CLTN | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 13.3 M | 17.3 M | 19.1 M | 14.9 M | 20 M | 8.2 M | 31.7 M | 26 M | 11.9 M | 20.5 M | 23.5 M | 19.9 M |
Roche Holding AG and related stocks such as Novartis AG, COSMO Pharmaceuticals, and Siegfried Holding Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Roche Holding AG | RO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Grenzacherstrasse 124, Basel, |
| Exchange | SIX Swiss Exchange |
CHF 364.8
Additional Tools for Roche Stock Analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.